DiaMedica Therapeutics to Participate in Upcoming Investor Conferences

DiaMedica Therapeutics will participate in two investor conferences in New York City. CEO Rick Pauls and CBO Dave Wambeke will hold one-on-one meetings and a corporate presentation at the H.C. Wainwright Global Investment Conference and participate in one-on-one meetings at the Lake Street Capital Markets Best Ideas Growth Conference Big 9. DiaMedica is a clinical-stage biopharmaceutical company focused on developing treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke, will participate in two prominent investor conferences in New York City. CEO Rick Pauls and Chief Business Officer Dave Wambeke will hold one-on-one meetings and a corporate presentation at the H.C. Wainwright Global Investment Conference and participate in one-on-one meetings at the Lake Street Capital Markets Best Ideas Growth Conference Big 9.

The H.C. Wainwright Global Investment Conference is scheduled for September 4-5, 2025, at the New York Marriott Marquis. Pauls and Wambeke will be available for corporate presentations and one-on-one meetings with investors. The Lake Street Capital Markets Best Ideas Growth Conference Big 9 is also set for September 4-5, 2025, with details on specific times and locations to be announced.

DiaMedica's lead candidate, DM199, is a pharmaceutically active recombinant form of the KLK1 protein, which has shown promise in treating acute ischemic stroke, preeclampsia, and other vascular diseases. The company's commitment to improving the lives of patients suffering from these conditions underscores its focus on innovative biopharmaceutical solutions.

For more information about DiaMedica Therapeutics Inc., visit their website at [www.diamedica.com](http://www.diamedica.com).

References:
[1] https://www.biospace.com/press-releases/diamedica-therapeutics-to-participate-in-cantor-global-healthcare-conference
[2] https://www.investing.com/equities/diamedica-therapeutics-inc